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Abstract. A common feature among pre-malignant lesions is 
the induction of hypoxia through increased cell propagation 
and reduced access to blood flow. Hypoxia in breast cancer 
has been associated with poor patient prognosis, resistance to 
chemotherapy and increased metastasis. Although hypoxia 
HAS BEEN correlated with factors associated with the latter 
stages of cancer progression, it is not well documented how 
hypoxia influences cells in the earliest stages of transformation. 
Using the immortalized MCF-10A breast epithelial cell line, 
we used hypoxic culture conditions to mimic reduced O2 levels 
found within early pre-malignant lesions and assessed various 
cellular parameters. In this non-transformed mammary cell 
line, O2 deprivation led to some changes not immediately asso-
ciated with cancer progression, such as decreased proliferation, 
cell cycle arrest and increased apoptosis. In contrast, hypoxia 
did induce other changes more consistent with an increased 
metastatic potential. A rise in the CD44+CD24-/low-labeled 
cell sub-population along with increased colony forming capa-
bility indicated an expanded stem cell population. Hypoxia 
also induced cellular and molecular changes consistent with 
an epithelial-to-mesenchymal transition (EMT). Furthermore, 
these cells now exhibited increased migratory and invasive 
abilities. These results underscore the contribution of the 
hypoxic tumour microenvironment in cancer progression and 
dissemination.
Introduction
Breast cancer is the most common malignancy in woman 
worldwide, and the second leading cause of cancer-related 
deaths in females (1). Considering that metastasis is responsible 
for 90% of these deaths (2), understanding the mechanisms 
which contribute to this endpoint is fundamental in the design 
of treatment strategies to alleviate breast cancer mortality. 
The pathological progression of breast cancer is well docu-
mented (3). However, the factors which govern this progression 
are less characterized (4). Considerable attention has been paid 
to the contribution of somatic mutation and epigenetic altera-
tions in cancer initiation and progression (5-7). However, the 
role of tumour-associated microenvironmental changes may be 
equally contributive and are only recently gaining impetus (8).
Hypoxia exemplifies one microenvironmental change 
associated with tumourigenesis. In the earliest stages of 
tumour development, abnormal proliferation and accumula-
tion of cells can lead to increased cellular mass, elevated 
intra-tissue pressure, insufficient perfusion and subsequent O2 
deficiency (9). In breast cancer patients, intra-tumour measure-
ments conducted in situ have revealed substantial levels of O2 
deprivation compared to normal breast tissue (10). Hypoxia 
in breast cancer has been associated with poor patient prog-
nosis (11-13), resistance to chemotherapy (14,15) and increased 
metastasis (13,16,17).
How hypoxia influences cancer progression is not fully 
defined. It is known that cells respond to reduced O2 avail-
ability by increasing the activity of hypoxia-inducible factors 
(HIF-1α and HIF-2α) which, in turn, mediate global transcrip-
tional changes (18). These transcriptional changes involve 
many genes and may alter various cellular processes which 
contributes to cancer progression (18). Numerous studies 
connecting hypoxia and cancer have been conducted on trans-
formed cells isolated from animal models, patient tumours and 
established cancer cell lines (19). However, these cells harbour 
many cancer-associated genetic and epigenetic changes. How 
hypoxia affects breast epithelial cells in the earlier stages of 
transformation remains less well defined.
In the present study, we used the untransformed MCF-10A 
breast epithelial cell line and hypoxic culture conditions to 
replicate conditions found within early hyperplastic breast 
lesions. Using this model we were able to study the effects of 
O2 deprivation independent from the contribution of cancer-
associated genetic and epigenetic changes. We demonstrated 
that reduced O2 availability induced a number of changes 
consistent with increased metastatic potential. Proliferation and 
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cell cycle progression were perturbed along with an increase 
in apoptosis. A rise in the CD44+CD24-/low cells coupled with 
an increased colony forming ability indicated a rise in the 
stem cell population. Cells underwent cellular and molecular 
changes consistent with epithelial-to-mesenchymal transition 
(EMT). Furthermore, hypoxia increased the migratory and 
invasive capabilities of these cells. Collectively, these results 
highlight the contribution of hypoxic microenvironmental 
changes in cancer progression and dissemination.
Materials and methods
Human tissue samples and ethics statement. Surplus breast 
tissue initially removed surgically for diagnostic purposes 
was used in the present study following informed patient 
consent. Archived paraffin-embedded tissue was obtained 
from Bristol Royal Infirmary under ethical approval from the 
NHS Health Research Authority and UWE Ethics Committee 
(Ref. 11/SW/0127). All methods were performed in accor-
dance with the NHS Health Research Authority guidelines 
and regulations.
Cell culture and hypoxia. MCF-10A cells were purchased from 
the American Tissue Culture Collection (ATCC; Manassas, 
VA, USA) and cultured in Dulbecco's modified Eagle's 
medium/Nutrient Mixture F-12 Ham supplemented with 
100 ng/ml cholera toxin (Sigma, St. Louis, MO, USA), 20 ng/ml 
epidermal growth factor (EGF) (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA), 10 µg/ml insulin, 500 ng/ml 
hydrocortisone and 5% heat-inactivated horse serum (all from 
Sigma). Experiments were conducted in the aforementioned 
media mixture excluding EGF (media was replaced at least 
24 h before experiments). MCF-10A cells were subjected to no 
>8 passages in culture before experiments. Whilst control cells 
were incubated at 37̊C in a humidified atmosphere containing 
5% CO2 and ~21% O2 (termed normoxia), hypoxic conditions 
(termed hypoxia) were induced using an airtight modular 
incubator chamber (Billups-Rothenberg, Inc., San Diego, CA, 
USA). Briefly, the cells were sealed in the modular incubator 
chambers with a sterile phosphate-buffered saline (PBS) 
reserve to maintain humidity, and then purged with a reduced 
O2 gas mixture (1% O2, 5% CO2 and 94% N2). The chamber 
was then sealed and placed in an incubator at 37̊C for 72 h.
Immunofluorescence microscopy. Paraffin blocks containing 
embedded human breast tissue were sectioned at 4 µm using a 
microtome (Leica RM2235) and mounted on Superfrost Plus 
slides (Thermo Fisher Scientific, Inc.). Sections were then depa-
raffinized with Histoclear (National Diagnostics, Atlanta, GA, 
USA) and rehydrated using a series of ethanol concentrations 
and dH2O. Antigen unmasking was performed by heating in 
citrate buffer (pH 6.0) using a water bath for 30 min (95-100̊C) 
and then allowing the sections to cool to room temperature 
(RT) in the buffer. Cultured MCF-10A cells were fixed with ice 
cold 4% paraformaldehyde for 20 min and then stored at 4̊C 
in 70% ethanol. The slides and/or fixed cells were incubated in 
blocking serum [goat serum (Vector Laboratories, Burlingame, 
CA, USA) diluted in Tris-buffered saline (TBS)] for 30 min at 
RT, and then incubated in a primary antibody overnight at 4̊C. 
Antibodies used were anti-human and are as follows: CA IX 
(a kind gift from Professor M. Ladomery), Ki-67 (Thermo 
Fisher Scientific, Inc.), cleaved caspase-3 (Cell Signaling 
Technology, Inc., Beverly, MA, USA), E-cadherin, β-catenin 
and vimentin (all from BD Biosciences, Franklin Lakes, NJ, 
USA). The following day, the slides and/or cells were washed 
in TBS and then incubated with suitable fluorescent-labelled 
secondary antibodies [Alexa Fluor (Thermo Fisher Scientific, 
Inc.)] for 1 h at RT. Subsequently, the slides and/or cells were 
washed with TBS, then mounted using Vectashield Hardset 
Mounting Media with 4,6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories). All images were obtained using a fluo-
rescence microscope (Nikon Eclipse 80i).
Western blot analyses. Cells were harvested in lysis buffer 
(10 mM Tris-HCl, 50 mM sodium chloride, 5 mM EDTA, 
15 mM sodium pyrophosphate, 50 mM sodium fluoride and 
100 µM sodium orthovanadate) supplemented with phos-
phatase (Roche Applied Science, Indianapolis, IN, USA) 
and protease (Sigma) inhibitor cocktails at 4̊C for 30 min. 
Following collection, the cells were sonicated on ice using 
Soniprep 150 (MSE Ltd., London, UK), then centrifuged at 
15,000 x g for 15 min at 4̊C and then the supernatant was 
collected. The protein concentration was determined using 
a Coomassie (Bradford) protein assay kit (Thermo Fisher 
Scientific, Inc.). An equal amount of protein from each 
sample was separated using 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel and 
transferred onto a nitrocellulose membrane (GE Healthcare, 
Little Chalfont, UK). After blocking with 5% milk powder 
for 1 h at room temperature, the membranes were incubated 
in a primary antibody overnight at 4̊C. The antibodies used 
were anti-human and are as follows: CA IX (a gift from 
Professor M. Ladomery), E-cadherin, β-catenin, vimentin 
(all from BD Biosciences) and β-actin (Thermo Fisher 
Scientific, Inc.) which was used as a loading control. The blot 
membrane was washed, then incubated with a horseradish 
peroxidase-conjugated secondary antibody, and signals were 
revealed using a chemiluminescence kit (Thermo Fisher 
Scientific, Inc.).
Proliferation and apoptosis scoring. Proliferation and apop-
tosis were assessed as a percentage of Ki-67-positive cells and 
a percentage of cleaved caspase-3-positive cells, respectively. 
Briefly, 10 evenly distributed x40 fields of view were imaged 
using a fluorescence microscope (Nikon Eclipse 80i) for each 
independent group. Positively-labeled cells were counted 
and scored as a percentage of total cells. Experiments were 
performed at least in triplicate for each group.
Flow cytometry. Cells were washed once with Hanks' balanced 
salt solution (HBSS) (Thermo Fisher Scientific, Inc.), and then 
harvested with 0.05% trypsin/0.025% EDTA (Thermo Fisher 
Scientific, Inc.). Detached cells were washed with HBSS 
containing 2% horse serum (Sigma) (wash buffer), and 
re-suspended in the wash buffer (106 cells/100 µl). Anti-human 
CD24-FITC-conjugated (BD Biosciences) and anti-human 
CD44-APC-conjugated (BioLegend, Inc., San Diego, CA, 
USA) antibodies or the respective isotype controls were added 
to the cell suspension, as recommended by the manufacturer, 
and incubated at 4̊C in the dark for 30 min. Subsequently, the 
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labelled cells were washed in wash buffer and then analysed 
on an Accuri C6 cytometer using CFlow Plus software (both 
from BD Biosciences).
Cell cycle analysis. Cells were harvested, washed with ice-cold 
PBS, and then fixed in 70% ethanol for at least 30 min at 4̊C. 
Before analysis, the cells were washed again in PBS, then 
incubated in staining buffer [100 µg/ml RNase and 50 µg/ml 
propidium iodide (PI) (Sigma)] in the dark at 4̊C for 30 min. 
The samples were analysed by flow cytometry using an 
Accuri C6 cytometer (BD Biosciences). CFlow plus software 
(BD Biosciences) was used to calculate the percentage of cells 
in the G0/G1, S and G2/M phases. All studies were performed 
in triplicate.
Mammosphere forming assay. Six-well culture plates were 
coated with poly(2-hydroxyethyl methacrylate) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) to obtain an ultra-
low adhesion surface. Following treatment, the cells were 
trypsinized and mechanically disrupted to obtain single-cell 
suspensions. The single-cell suspensions were then plated at 
1x103 in 1 ml MCF-10A medium in the ultra-low adhesion 
wells. The cells were left to form spheres for 10 days, and 
mammospheres were considered cell aggregates >50 µm in 
diameter. The mammospheres were imaged, counted and 
measured using a phase-contrast inverted microscope (Nikon 
Eclipse TE300). Each experiment was repeated in triplicate.
Wound healing assay. Cells were plated in 6-well culture 
plates, and wounds were inflicted upon the cell monolayers 
using a sterile plastic 200-µl micropipette tip. Phase-contrast 
microscopy images were immediately obtained after 
wounding and again 48 h later using an inverted microscope 
(Nikon Eclipse TE300). The experiments were independently 
performed in triplicate, and the migration distance under 
each condition was assessed by analyzing the images using 
ImageJ software (National Institutes of Health, Rockville, 
MD, USA).
Transwell invasion assay. Transwell inserts (Millipore, 
Billerica, MA, USA) containing polycarbonate filters with 
8-µm pores were used in the assay. The inserts were coated 
with 50 µl of Matrigel matrix (1 mg/ml) according to the 
manufacturer's recommendations (Thermo Fisher Scientific, 
Inc.). The cells were seeded in the upper chambers of the 
inserts at a density of 2x105 cells in 1 ml serum-free MCF-10A 
medium. MCF-10A medium (2 ml) containing serum was 
placed in the lower chambers. Following 72 h of treatment, 
the cells on the upper surface of the membrane were removed 
using a methanol coated cotton swab. The cells on the lower 
chamber were fixed in 4% paraformaldehyde and stained with 
hematoxylin (Sigma). For each membrane, the number of cells 
was counted in 10 evenly distributed x40 fields of view using 
a light microscope (Nikon Eclipse 80i). Each experiment was 
repeated in triplicate.
Statistical analysis. Data for each group are presented as the 
mean ± SD. Statistical analyses were performed using SPSS 
for Windows, version 20.0 (IBM SPSS, Inc., Chicago, IL, 
USA). Values of P<0.05 were deemed statistically significant.
Results
Hypoxic conditions induce upregulation of carbonic anhy-
drase (CA IX). CA IX is a downstream target of HIF-1α and 
a robust marker of hypoxia (20). To assess the consequence 
of abnormal breast cell propagation on intracellular O2 
levels, sections of hyperplastic breast tissue were labeled 
for CA IX and compared to control tissue (Fig. 1A). Whilst 
CA IX expression was undetectable in control tissue, 
upregulation was prominent within hyperplastic tissue with 
the highest expression observed within the center of lesions 
corresponding to areas with the most limited access to blood 
supply.
To model hypoxic conditions found within the breast 
tumour microenvironment and delineate-associated conse-
quences, MCF-10A cells were cultured in hypoxic conditions 
(1% O2) for 72 h and compared to cells cultured in normoxia 
(21% O2). Previous studies have suggested a level of ~1% O2 is 
found within the breast tumour microenvironment (21). Whilst 
control MCF-10A cells cultured in normoxia displayed unde-
tectable levels of CA IX expression, MCF-10A cells cultured 
under hypoxic conditions displayed an increase in CA IX 
expression detected by both fluorescence microscopy (Fig. 1B) 
and western blot analysis (Fig. 1C).
Hypoxia reduces proliferation, induces apoptosis and 
perturbs cell cycle progression. Increased cell division and 
evasion of cell death are both prominent features in most 
tumours (22). To assess the effects of hypoxia on cell division, 
proliferation was analysed by monitoring changes in Ki-67 
expression (Fig. 2A). A statistically significant reduction in the 
percentage of Ki-67 positive cells was observed in MCF-10A 
cells cultured under hypoxic conditions in comparison to those 
cultured in normoxia (2.50±1.28 compared to 29.53±3.89% 
respectively; P<0.05) (Fig. 2B). To assess the effects of hypoxia 
on cell death, apoptosis was analysed using cleaved caspase-3 
expression (Fig. 2C). A statistically significant increase in the 
percentage of cleaved caspase-3 positive cells was observed in 
MCF-10A cells cultured under hypoxic conditions compared 
with those cultured in normoxia (3.91±1.12 compared to 
0.35±0.18% respectively; P<0.05) (Fig. 2D).
Given the decrease in proliferation and increase in 
apoptosis in MCF-10A cells cultured in hypoxia and the link 
between these parameters and cell cycle progression, cell cycle 
distribution analysis was performed using PI staining and 
flow cytometry (Fig. 2E). ‘Gating’ was performed in analyses 
to include live cells in the G0/G1, S or G2/M phases whilst 
excluding debris and/or necrotic cells. MCF-10A cells cultured 
in normoxia had the following distribution: G0/G1 phase, 
74.27±0.81%; S phase, 5.63±0.32%; and G2/M phase, 
18.57±1.30%, whilst MCF-10A cells cultured in hypoxia 
had this distribution: G0/G1 phase, 63.83±1.63%; S phase, 
3.33±0.25%; and G2/M phase, 32.40±3.15%. As shown in 
Fig. 2F, MCF-10A cells cultured in hypoxic conditions had a 
statistically significant decrease in the percentage of cells in 
the G0/G1 and S phases (P<0.05), compared to MCF-10A cells 
cultured in normoxia. Conversely, a statistically significant 
increase in the percentage of cells in the G2/M phase (P<0.05) 
was observed in MCF-10A cells cultured in hypoxia compared 
to MCF-10A cells cultured in normoxia. Collectively, these 
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Figure 1. CA IX expression marks hypoxia in human breast tissue. (A) Serial sections of human breast tissue were stained with H&E or labeled for CA IX using 
fluorescent immunohistochemistry (scale bar represents 200 µm in low magnification; 50 µm in high magnification; * denotes the region furthest away from 
blood supply). (B) MCF-10A cells were placed in 20% O2 or 1% O2 culture conditions for 72 h then labeled for CA IX using fluorescent immunohistochem-
istry (scale bar represents 10 µm). (C) The expression levels of CA IX in MCF-10A cells were detected by western blotting, β-actin served as a loading control.
Figure 2. Hypoxia reduces proliferation, perturbs cell cycle progression and induces apoptosis. (A) Cells were labeled for Ki-67 using fluorescent immu-
nohistochemistry (scale bar, 25 µm). (B) Percentage of Ki-67 positive cells (error bars ± standard deviation, *P≤0.05, Mann-Whitney U test, n≥3). (C) Cells 
were labeled for cleaved caspase-3 using fluorescent immunohistochemistry (scale bar, 25 µm). (D) Percentage of cleaved caspase-3 positive cells (error 
bars ± standard deviation, *P≤0.05, Mann-Whitney U test, n≥3). (E) Cell cycle distribution was evaluated using flow cytometry. (F) Graph displays the cell 
cycle phase expressed as a percentage of total cells (error bars ± standard deviation, *P≤0.05, Mann-Whitney U test, n≥3).
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Figure 3. Hypoxia increases the stem/progenitor cell population. (A) Flow cytometric analysis of CD44 and CD24 cell surface markers. Percentage of 
CD44+CD24-/low stained cells displayed. (B) Photomicrographs of mammospheres formed after 7 days (scale bar represents 100 µm). (C) Average number 
of mammospheres formed/well (error bars ± standard deviation, *P≤0.05, Mann-Whitney U test, n≥3). (D) Average size of formed mammospheres (error 
bars ± standard deviation, *P≤0.05, Mann-Whitney U test, n≥3).
Figure 4. Hypoxia induces EMT, increased migration and invasion. (A) Cells were labeled for E-cadherin, β-catenin and vimentin using fluorescent immu-
nohistochemistry (scale bar, 25 µm). (B) The levels of protein expression of E-cadherin, β-catenin and vimentin were detected by western blotting, β-actin 
served as a loading control. (C) Scratch wound migration assays were performed on confluent cells. Red dotted lines indicate the wound borders at the 
beginning of the assay. Lower panel displays comparative unscratched area. (D) Relative wound gap calculated as a ratio of the remaining wound gap at 48 h 
and the original wound gap at 0 h (error bars ± standard deviation, *P≤0.05; Mann-Whitney U test, n≥3). (E) Phase contrast images of migratory leading edge. 
(F) Photomicrographs of invaded cells in Matrigel Transwell assay. (G) Average number of invaded cells/field of view (error bars ± standard deviation, *P≤0.05; 
Mann-Whitney U test, n≥3).
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data revealed that hypoxia can regulate cell growth and can 
block cell cycle progression in the G2/M phase.
Hypoxia increases the stem cell population. Previous studies 
have utilized the cell surface markers CD44 and CD24 to 
distinguish a CD44+CD24 -/low sub-population which is 
enriched for stem cells/cancer stem cells (23,24). Using flow 
cytometric analysis (Fig. 3A), we revealed that MCF-10A 
cells cultured under hypoxic conditions displayed a higher 
percentage of cells in the CD44+CD24-/low sub-population 
in comparison to MCF-10A cells cultured in normoxia (2.2% 
in comparison to 1.3%, respectively). Mammosphere assays 
have been previously used as a surrogate reporter of stem cell 
activity (25,26), and an increase in the number and/or size 
of formed colonies are indicative of an expanded stem cell 
population. MCF-10A cells grown in normoxia or hypoxia 
were seeded in low adhesion culture vessels, left to form 
spheres in normoxia and then compared (Fig. 3B). Following 
re-oxygenation, MCF-10A cells cultured in hypoxia displayed 
a statistically significant increase in both mammosphere 
forming efficiency (33.50±6.56/well compared to 19.50±3.11/
well, respectively; P<0.05) (Fig. 3C) and mammosphere 
size (88.78±11.57 compared to 63.49±4.77 µm respectively, 
P<0.05) (Fig. 3D) in comparison to MCF-10A cells initially 
cultured in normoxia. Collectively, these results suggest that 
hypoxic conditions lead to an expansion of the stem cell popu-
lation.
Hypoxia induces EMT, increases migration and invasion. 
EMT is a process in which epithelial cells lose epithelial 
characteristics and acquire mesenchymal properties. It is 
recognized as an important event in the progression and 
dissemination of cancer (27). MCF-10A cells cultured in 
hypoxia or normoxia were labeled for E-cadherin, β-catenin and 
vimentin using fluorescent immunohistochemistry (Fig. 4A). 
MCF-10A cells cultured in hypoxic conditions displayed a 
loss of total and membrane bound E-cadherin, a loss of total 
and membrane bound β-catenin (although no nuclearization 
was apparent) concomitant with an upregulation of vimentin 
expression. Collectively, these expression changes along with 
characteristic changes noticed in cell shape are indicative of 
EMT (28,29). Total levels of protein expression, as detected 
by western blotting, confirmed global changes (Fig. 4B). 
Migratory and invasive capabilities are further traits acquired 
by cells to allow cancer metastasis (30). Scratch wound assays 
were used to assess the migratory ability of MCF-10A cells 
cultured in hypoxia vs. normoxia (Fig. 4C). MCF-10A cells 
cultured under hypoxic conditions displayed an increase in 
migratory ability. Comparative unscratched areas demonstrate 
highly polarized and tightly packed cells following normoxic 
culture conditions whilst following hypoxia, cells lose 
their tightly packed formation and appear more sporadic. 
Collectively, this suggests that wound closure is due to 
increased migratory abilities rather than an increase in cell 
numbers. Quantitative analysis of wound gap closure (Fig. 4D) 
revealed a statistically significant increase in gap closure and 
thus a higher rate of migration in MCF-10A cells cultured 
under hypoxic conditions (relative gap remaining after 48 h 
in normoxic culture conditions 0.68±0.091 compared to 
0.12±0.1 in cells cultured under hypoxic conditions; P<0.05). 
Higher magnification of MCF-10A cells at the leading edge of 
migration revealed the extent of changes in cell shape and a 
more ‘mesenchymal/fibroblastic’ appearance of cells cultured 
in hypoxia as opposed to normoxia (Fig. 4E). A Matrigel 
Transwell invasion assay was used to compare and analyze 
the invasive capacity of MCF-10A cells cultured in hypoxia 
vs. normoxia. Whilst cells cultured in normoxia displayed 
a limited ability to move across the Matrigel barrier, cells 
cultured in hypoxic conditions were readily observed on the 
bottom of the insert (Fig. 4F). Quantification of these cells 
revealed a significant increase in the number of invaded cells 
in cells cultured under hypoxic conditions in comparison to 
those cultured in normoxia (42.2±8.57/field of view compared 
to 0.77±0.05/field of view respectively; P<0.05). Collectively, 
these results revealed that O2 deprivation in MCF-10A cells 
can lead to changes consistent with EMT, increased migratory 
ability and increased invasive capabilities.
Discussion
As metastasis is responsible for ~90% of cancer-related 
deaths (2), underscoring the mechanisms that contribute 
to cancer dissemination are vital in our understanding of 
the disease and may thus help expose potential preventative 
strategies. Whilst considerable attention has been paid to 
the contribution of genetic and epigenetic alterations in this 
pathological process (5-7), the importance of tumour micro-
environmental changes are beginning to be exposed (8). In 
the present study, we used hypoxic conditions to replicate 
an important microenvironmental change associated with 
tumourigenesis. MCF-10A cells were exposed to low O2 levels 
to replicate conditions found within the earlier stages of breast 
tumourigenesis. O2 deprivation led to some changes not imme-
diately associated with tumourigenesis, such as decreased 
proliferation, cell cycle arrest and increased apoptosis. In 
contrast, hypoxia-induced changes were more consistent with 
a progression towards metastatic disease, such as an increase 
in ‘stemness’, induction of EMT and increased migratory and 
invasive capabilities.
Previous studies have linked hypoxia with reduced 
proliferation in breast cancer cell lines and ductal carcinoma 
in situ (31), a precursor of invasive ductal carcinoma. HIF-1α 
expression has been observed at this early stage of breast tumour 
development (31,32), and has been revealed to both inhibit 
transcription (33), and promote degradation (34) of c-MYC, an 
essential regulator of cellular growth and the cell cycle (35). 
Cell cycle progression was attenuated at the G2/M phase in 
our model and may represent a further mechanism for our 
observed reductions in proliferation. Previous studies have 
linked hypoxia with several G2/M checkpoint regulators and 
blockage of cell cycle progression at this phase (36,37) and 
this has been reported to contribute to increased chemo- and/
or radio-resistance in some tumours (38,39). The induction of 
apoptosis in our model may also be explained through HIF-1α 
expression. HIF-1α has previously been reported to promote 
apoptosis (40,41). This, in part, could be explained by stabili-
zation of p53 by HIF-1α (42) and/or by increased transcription 
of HIF-1α targets which are pro-apoptotic such as NIP3 (43).
Given that sustaining proliferative signaling and resisting 
cell death are ‘hallmarks’ of cancer (22), reduced proliferation, 
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cell cycle arrest and increased apoptosis induced by hypoxia 
may seem disadvantageous for tumourigenesis. However, 
previous studies have demonstrated that hypoxia can exert 
a selective pressure whereby cells with accumulated genetic 
alterations, such as the loss of p53 (44), gain a selective 
advantage and constitute the tumour (44,45). Furthermore, it is 
known that hypoxia can increase mutation frequency and lead 
to genomic instability (46). This is most likely due to the effects 
of hypoxia on the DNA damage response exerted through both 
HIF-1α dependent (47) and HIF-1α independent means (48). 
Collectively, these changes can lead to the generation of cells 
which possess the genetic and epigenetic adaptations essential 
for tumour progression into metastatic disease.
Hypoxia in our model also induced an increase in the stem 
cell population. The link between stem cells and cancer is 
well documented (49,50), and cancer stem cells are reportedly 
responsible for initiating metastatic growth in various cancers 
including breast (23,51,52). Previous studies have reported 
a less differentiated phenotype and/or an increase in stem-
ness induced by hypoxia in breast tumour tissue (31,53,54). 
Increases in stemness can, in part, be explained by the ability 
of HIF-1α and HIF-2α to induce various transcriptional 
programs, some of which include pluripotency factors (55,56). 
The consequence of hypoxia-induced increases in stem cell 
numbers in early neoplastic lesions and the contribution of 
this to metastatic disease may be two-fold. First, an increase in 
stem cell numbers due to hypoxia along with the increased rate 
of mutation may increase the chance of oncogenic mutations 
occurring within stem cell populations leading to cancer stem 
cells. Second, hypoxia leading to an increase in the number of 
cancer stem cells may lead to an increase in metastatic poten-
tial. These reasons may contribute to why hypoxia is linked to 
increased metastatic disease (13,16,17).
A more direct involvement of hypoxia in metastasis is eluci-
dated from the induction of EMT observed in our model along 
with the increased migratory and invasive behavior of these 
cells. As mentioned previously, EMT is an important event 
in the progression and dissemination of cancer (27). Previous 
studies have linked hypoxia, EMT, increased migration and 
invasion to various cancer cell lines including breast (57-59). 
This most likely occurs through HIF-1α- and HIF-2α-related 
transcriptional changes (60). In the present study we demon-
strated that hypoxia-induced EMT, increased migratory and 
invasive behavior in untransformed cells. Given that metastasis 
occurs in the later stages of cancer progression following an 
accumulation of genetic and epigenetic alterations, the signifi-
cance of this finding remains unclear. However, a mechanistic 
dissection of the roles of HIF-1α and HIF-2α isoforms at this 
early stage of transformation and the relevance of their true 
input warrant further investigation and should be the basis of 
further experiments.
To conclude, the present study provided evidence that 
tumour-associated microenvironmental changes have a 
substantial role alongside genetic and epigenetic alterations 
in the progression of breast cancer. Hypoxia can occur in the 
earliest stages of tumourigenesis and influence various cellular 
processes associated with metastatic potential. Although the 
present study uses a simplistic approach to delineate the 
contributions of the hypoxic microenvironment from the 
myriad of genetic and epigenetic alterations found in human 
tumours; in reality, understanding the interactions between 
these co-contributors may elucidate the true factors driving 
metastasis in human disease.
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